The Vanguard Group, Inc. has recently announced that it has increased stake in AbbVie Inc. (NYSE:ABBV) by 1.65%. After grabbing 148.48 million shares, the institutional investor is now in possession of 2.42 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 8.40% having worth around $21.74 billion. Moreover, BlackRock Fund Advisors increased its share by 0.58 million to have a control over 85.68 million shares. And SSgA Funds Management, Inc. raised its holdings to 0.37 million shares by acquiring 77.49 million shares or 4.38% of the stake.
AbbVie Inc. (ABBV) concluded trading on 11/30/22 at a closing price of $161.18, with 12.24 million shares of worth about $1.97 billion changed hands on the day. Half year performance of the stock remained positive as price took a surge of 10.38% during that period and on Wednesday the price saw a gain of about 1.88%. Currently the company’s common shares owned by public are about 1.77B shares, out of which, 1.77B shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 25 analysts are covering the ABBV stock and their offered price forecasts bring an average price target of $159.15. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $200.00 and could fall to a lowest price of $133.00. The stock’s current price level is -1.09% below of average price target set by the analysts, while a dip to estimated low would result in loss of -21.19% for the stock. However, touching the estimated high of $200.00 would mean a gain of 19.41% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 159 times over the past 12 months. They bought 2,041,476 shares in 82 of the transactions. In 77 selling transactions, insiders dumped 1,752,529 shares.
Vanguard Total Stock Market Index, Vanguard 500 Index Fund, and SPDR S&P 500 ETF Trust are the top 3 mutual funds which are holding stakes in AbbVie Inc. Vanguard Total Stock Market Index is currently holding 53.06 million shares of worth totaling $7.77 billion. The company recently came buying 0.26 million shares which brought its stake up to 3.00% of the company’s outstanding shares. Vanguard 500 Index Fund bought 0.39 million shares, after which its hold over company’s outstanding shares expand to 2.29%, leaving 40.46 million shares with the mutual fund that have a worth of about $5.92 billion. SPDR S&P 500 ETF Trust, after selling 19.9 million shares, have now control over 1.13% of the stake in the company. It holds -0.2 million shares of worth $2.91 billion.
AbbVie Inc. (NYSE: ABBV) started trading at $158.79, above $0.59 from concluding price of the previous day. However, the stock later moved at a day high price of 161.18, or with a gain of 1.88%. Stock saw a price change of 0.87% in past 5 days and over the past one month there was a price change of 10.10%. Year-to-date (YTD), ABBV shares are showing a performance of 19.04% which increased to 39.82% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $115.10 but also hit the highest price of $175.91 during that period. The average intraday trading volume for AbbVie Inc. shares is 5.50 million. The stock is currently trading 5.98% above its 20-day simple moving average (SMA20), while that difference is up 9.71% for SMA50 and it goes to 8.31% higher than SMA200.
The Vanguard Group, Inc. acquired 148.48 million shares of AbbVie Inc. having value of about $21.74 billion. Data submitted at the U.S SEC by The Vanguard Group, Inc. revealed that the firm now holds 2.42 million shares in the company valued at close to $389260821.42, or have control over 1.65% stake in the company. AbbVie Inc. (NYSE: ABBV) currently have 1.77B outstanding shares and institutions hold larger chunk of about 70.90% of that. Holding of mutual funds in the company is about 30.74% while other institutional holders and individual stake holders have control over 39.82% and 0.13% of the stake respectively.
The stock has a current market capitalization of $285.76B and its 3Y-monthly beta is at 0.67. PE ratio of stock for trailing 12 months is 21.47, while it has posted earnings per share of $7.51 in the same period. It has Quick Ratio of 0.80 while making debt-to-equity ratio of 4.35. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ABBV, volatility over the week remained 1.71% while standing at 2.16% over the month.
Analysts are in expectations that AbbVie Inc. (ABBV) stock would likely to be making an EPS of $3.57 in the current quarter, while forecast for next quarter EPS is $3.75 and it is $11.84 for next year. For the current quarter EPS, analysts have given the company a lowest target $3.51 which is $3.7 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $2.83 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 137.00% while it is estimated to decrease by -16.73% in next year. EPS is likely to shrink at an annualized rate of -0.40% for next 5-years, compared to annual growth of 12.20% made by the stock over the past 5-years.
Analysts at 25 brokerage firms have issued recommendations for the AbbVie Inc. (ABBV)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.30. Out of those 25 Wall Street analysts, 13 recommended a “Buy” rating, while 10 were in favor recommending the stock as a “Hold” and 1 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Credit Suisse on November 18, 2022 offering an Outperform rating for the stock and assigned a target price of $170 to it. On August 01, 2022, Atlantic Equities Downgrade their recommendations, while on May 23, 2022, SVB Leerink Initiated their ratings for the stock with a price target of $140. Stock get a Neutral rating from Daiwa Securities on May 06, 2022.